|
|
Volumn 4, Issue 1, 2008, Pages 1-2
|
|
Criteria for deciding cost-effectiveness for expensive new anti-cancer agents
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CETUXIMAB;
ERYTHROPOIETIN;
FLUDARABINE;
ADVANCED CANCER;
CANCER CHEMOTHERAPY;
COLORECTAL CANCER;
COST EFFECTIVENESS ANALYSIS;
ECONOMIC ASPECT;
EDITORIAL;
FUNDING;
GOVERNMENT;
HEALTH CARE COST;
HUMAN;
INDIA;
QUALITY OF LIFE;
RESOURCE ALLOCATION;
RISK BENEFIT ANALYSIS;
|
|
EID: 42349117539
PISSN: 09731482
EISSN: 19984138
Source Type: Journal
DOI: 10.4103/0973-1482.39685 Document Type: Editorial |
|
Times cited : (33)
|
|
References (0)
|
